ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
US clears Cara, Vifor's Korsuva to treat itching in CKD patients
August 24, 2021Cara Therapeutics and Vifor Pharma said Monday that the FDA has approved Korsuva (difelikefalin) to treat moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing haemodialysis. -
Enteris BioPharma Receives $10M Milestone from Cara Therapeutics
June 15, 2021The contract development and manufacturing organization (CDMO) Enteris BioPharma received a $10 million milestone payment from Cara Therapeutics related to the license agreement for the Peptelligence oral formulation technology utilized in ... -
Cara Therapeutics Announces Positive Topline Data from Oral KORSUVA Trial
December 30, 2019Cara Therapeutics announced positive topline results from its Phase 2 dose-ranging trial of Oral KORSUVA™ (CR845/difelikefalin) for the treatment of pruritus in patients with ... -
Enteris, Cara Therapeutics Enter Peptelligence Pact
August 27, 2019Cara has a non-exclusive, royalty-bearing license to the Peptelligence technology to develop, manufacture and commercialize Oral KORSUVA
Pharma Sources Insight January 2025
